Small Molecule Drug Clinical Trials - Laboratory Solutions
Due to the complexity of tumor biology, tumor drug development is full of challenges. Compared with other diseases, Hematological malignancies require multi-omics platforms (M: morphology, I: immunology, C: cytogenetics, M: molecular biology, etc.) to provide necessary information for disease diagnosis, treatment, prognosis, etc., and rely on the services provided by the central laboratory.
KingMyLab has established a sound MICM and other multi-omics platforms, which can fully support the research of biomarkers related to Hematological malignancies drug development. At present, we have helped more than 300 clinical research projects of Hematological malignancies , involving small molecules, monoclonal antibody/double antibody and other macromolecules, CAR-T (chimeric antigen receptor T cell) and other therapies, covering diseases such as leukemia, lymphoma and multiple myeloma.
Pharmacokinetics (PK) Study
Servies: Drug Concentration, Absorption, Distribution, Metabolism, Excretion, etc.
Platforms: Mass Spectrometry,etc.
Disease Diagnosis for Patient Inclusion and Exclusion
Servies: Blood Smear, Bone Marrow Smear, Histopathology, Immune Typing, Karyotype and Chromosome Variation, Genetic Mutation or Rearrangement, Blood, Urine Tests, etc.
Platforms: Karyotyping, FISH, CMA, qPCR, NGS, etc.
Prognosis Assessment
Servies: Karyotype, Chromosome Variation, Gene Mutation or Rearrangement, etc.
Platforms: Karyotyping, FISH, CMA, qPCR, NGS, etc.
Therapeutic Response
Servies: Target Gene Mutation or Rearrangement, Target Antigen Positive Cells, etc.
Platforms: FISH, qPCR, NGS, etc.
Pharmacodynamics Biomarkers
Servies: Target Gene Mutation or Rearrangement, Target Antigen Positive Cells, etc.
Platforms: FISH, qPCR, NGS,etc.
Safety Biomarkers
Servies: Cytokines and Inflammation-Related Markers, etc.
Platforms: LBA, Olink, etc.
Disease Monitoring
Servies: Minimal Residual Disease (MRD) Monitoring, ctDNA, etc.
Platforms: Flow, NGS, qPCR, Digital PCR, etc.
